同共同研究は、塩野義製薬のワクチン開発とアジュバント技術のノウハウを活かし、有効性、安全性及び利便性に優れた抗体誘導ペプチドの新規アジュバントを探索することを目的としている。主に塩野義製薬が新規アジュバントの製剤検討を行い、同社は動物試験での薬効評価及び安全性評価を行う予定である。On the 11th, Fan Pep <4881> announced that they have started a joint research with Shionogi <4507> on a new adjuvant for antibody-inducing peptides.
Antibody-inducing peptides are peptide vaccine therapies that are expected to have therapeutic effects by inducing antibody production against target proteins in the patient's body. Adjuvants are substances used to enhance the effectiveness when administered together with a vaccine to improve the effects of the vaccine injection.
The company is strengthening its research and development pipeline by utilizing its antibody-inducing peptide drug discovery platform technology based on the functional peptide 'AJP001' to create candidate compounds of antibody-inducing peptides for various target proteins. In parallel with the creation of candidate compounds, they are also conducting research on various next-generation formulation technologies that induce powerful antibody production, including adjuvant technology.
The joint research aims to explore a new adjuvant for antibody-inducing peptides that excel in effectiveness, safety, and convenience by leveraging Shionogi's vaccine development and adjuvant technology expertise. Shionogi will mainly conduct formulation considerations for the new adjuvant, while the company plans to conduct efficacy and safety evaluations in animal studies.
The company will bear the costs related to the responsibilities of the joint research, with no changes to the research and development cost forecast for the fiscal year ending December 2024.
